Clinical Trial Update: Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Phase 2]

View source ↗

Summary

This is a completed Phase 2 study of Iressa (gefitinib) in patients with relapsed or refractory acute myeloid leukemia. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Myelogenous Leukemia, Acute | Phase 2 | Status: COMPLETED